Authors/reference | Study description | No. of patients included | No. of prior regimen | Everolimus dosage | Best responses | Duration of response | Safety |
---|---|---|---|---|---|---|---|
Thiery-Vuillemin A et al. [9] | Case reports | 2 | 1; 1 | 5 mg | NA | NA | Grade II asthenia, diarrhea and mucositis; grade III hyperglycemia |
Syrios J et al. [10] | Case reports | 2 | 1; 1 | 10 mg | SD; CR | 4 mo; 40 mo | Well tolerated |
Adytia V et al. [11] | Single institution experience | 6 | NA | 10 mg; 1 dosage reduction to 5 mg | SD | Median duration of therapy 1.9 mo (0.4–17) | 5 patients: well tolerated, 1 patient: pneumonitis |
Czarnecka AM et al. [12] | Single institution experience | 1 | 2 | 10 mg | PD | 4 mo | Well tolerated |
Omae K et al. [13] | Single institution experience | 4 | 1 | SD | Median duration of therapy 6.7 mo | Grade II rash, diarrhea, pneumonitis, and mucositis |